Fresenius raises 2026 outlook for second time as FMC cuts its own
Reuters via Global Banking & Finance · · AI-summarised by FinFlash
Fresenius lifted its full-year 2026 expectations after a stronger than anticipated third quarter led by its Kabi and Helios units. It now sees constant-currency core EPS growth at the upper end of its 10%-15% range and an EBIT margin above 11.5%, against about 11.5% before. It is the second upgrade this year after August. Fresenius Medical Care, 25% owned, cut its operating income outlook after a third straight quarterly fall in US treatment volumes.
So What?
Supportive for German healthcare names, with Fresenius up 4.31% in early Frankfurt trade. FMC's falling US volumes are the risk to watch for the wider dialysis group.
Understand the context
Published information may change. Summaries can contain errors; check the original source. Educational information only, not investment advice.